Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pridopidine (ACR16) in Huntington's Disease (HART)
NCT00724048Phase 2Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Oct 2008
- Primary completion
- Jul 2010
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of pridopidine in Huntington disease (HD), sponsored by Teva Pharmaceutical Industries Ltd.. Started Oct 2008; status: completed.
02
Drugs
pridopidine
03
Conditions
Huntington disease (HD)
Beyond the preview
Go deeper on NCT00724048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00724048.